SCHEMBL95577

SCHEMBL95577

[CH2]c1ccc(NC(=O)Oc2ccc(C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
GAA P10253 4/20 0.53
MAPT P10636 4/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KDM4E B2RXH2 3/20 0.51
THRB P10828 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
GFER P55789 2/20 0.51
GLA P06280 1/20 0.51
BLM P54132 1/20 0.51
CASP6 P55212 1/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 2/20 0.51
TP53 P04637 1/20 0.51
PORCN Q9H237 1/20 0.49
RAB9A P51151 2/20 0.49
FAAH O00519 1/20 0.48
RAD51 Q06609 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10192033 0.91 ALDH1A1 (0.61) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL94538 0.87 SMN1; SMN2 (0.71) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL15167068 0.85 ALDH1A1 (0.54) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL12407138 0.85 SMN1; SMN2 (0.73) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL10192035 0.83 KMT2A (0.55) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL10192034 0.83 FAAH (0.67) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL95221 0.83 GAA (0.51) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL10708813 0.83 GAA (0.55) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL97442 0.83 GAA (0.51) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL10192032 0.83 KMT2A (0.54) ALDH1A1GAAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
CN-101068810-B Carbostyril compound OTSUKA PHARMA CO LTD 2011-02-09 CN disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
CN-101068810-A Carbostyril compound OTSUKA PHARMA CO LTD (JP) 2007-11-07 CN disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB ALDH1A1 2948/4885GAA 4574/4885MAPT 4112/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 ALDH1A1 2458/4885GAA 4784/4885MAPT 4773/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 ALDH1A1 2458/4885GAA 4784/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.